ClinicalTrials.gg
CompletedNCT04136873Updated Jul 2, 2021

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

A Phase 1 interventional study of CVL-231 and Matching Placebo in Schizophrenia, sponsored by Cerevel Therapeutics, LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-07-02.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Enrollment
20th of 27
130 · median 268
Started
2019
the only one that year
Phase 1
6 of 27
none open now
Registered
18th of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 20th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 1, and was the 18th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a primary diagnosis of schizophrenia per , as confirmed by the MINI.
  2. Subjects with the following scores on the PANSS at time of signing ICF and at Day -1: • Positive Subscale 7 (hostility) ≤3 (normal to moderate) • General Psychopathology Subscale 8 (uncooperativeness) ≤3 (normal to moderate)
  3. Subjects with the following scores (normal to mild symptoms) at time of signing ICF and at Day -1: • All individual items of the Modified SAS (M-SAS) \<2 • All individual items (Items 1-7) of the Abnormal Involuntary Movement Scale (AIMS) \<2 • Clinical global assessment item of the Barnes Akathisia Rating Scale (BARS) \<3
  4. of 17.5 to 38.0 kg/m2 and a total body weight >50 kg (110 lbs).

Cohorts 1 Through 5 (Part A):

Subjects are eligible to be included in trial (Cohorts 1 through 5) only if all of the following additional criteria apply:

  1. Male and female subjects, ages 18 to 50 years, inclusive.
  2. Subjects with a score on the CGI-S ≤4 (normal to moderately ill) at time of signing ICF and at Day -1.
  3. Subjects with a PANSS total score of ≤80 at the time of signing ICF and at Day -1.

Cohort 6 (Part B):

Subjects are eligible to be included in trial (Cohort 6) only if all of the following additional criteria apply:

  1. Male and female subjects, ages 18 to 55 years, inclusive.
  2. Subjects with a score on the CGI-S ≥4 (moderately to severely ill) at time of signing ICF and at Day -1.
  3. Subjects with a PANSS total score of ≥80 at the time of signing ICF and at Day -1. Additionally, subjects must meet a score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale items at the time of signing ICF and at Day -1:

    • Positive Scale 1 (delusions)
    • Positive Scale 2 (conceptual disorganization)
    • Positive Scale 3 (hallucinatory behavior)
    • Positive Scale 6 (suspiciousness/persecution)
  4. Subjects with a history of relapse and/or exacerbation of symptoms when not receiving antipsychotic treatment, excluding the current episode.
  5. Subjects must be experiencing an acute exacerbation or relapse of symptoms, with onset less than 2 months prior to signing ICF.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a current diagnosis other than schizophrenia including, but not limited to, mental retardation; schizoaffective disorder; schizophreniform disorder; psychotic depression; major depressive disorder; bipolar disorder; post-traumatic stress disorder; generalized anxiety disorder, obsessive compulsive disorder, eating disorders (bulimia, anorexia), or other anxiety disorders as a primary diagnosis (subjects with anxiety symptoms secondary to schizophrenia are allowed); delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  2. Subjects with schizophrenia who were considered resistant/ to antipsychotic treatment by history or who had a history of failure to respond to clozapine or response to clozapine treatment only.
  3. Subjects with EPS being treated with a medication that required dose modification and/or new treatment within 6 months prior to signing ICF.
  4. Subjects with a current history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine (including newly diagnosed diabetes mellitus or subjects with known diabetes mellitus with glycosylated ()>7.5%), hematological, immunological, psychiatric (excluding schizophrenia), or neurological disease.
  5. Subjects with a current or past history of significant cardiovascular disease.
  6. Subjects who experienced acute depressive symptoms within the past 30 days.
  7. Subjects with epilepsy or a history of seizures, except for a single seizure episode, eg, a childhood febrile seizure, or a seizure related to trauma or alcohol withdrawal.
  8. An active central nervous system infection, demyelinating disease, degenerative neurological disease, mental retardation, or any central nervous system disease deemed to be progressive.
  9. History of moderate to severe substance or alcohol-use disorder (excluding nicotine or caffeine) as per DSM-5 criteria within 12 months prior to signing ICF.
  10. Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent).
  11. seropositive status or acquired immunodeficiency syndrome, chronic or C.
  12. Subject with a positive urine drug screen for illicit drugs or a positive breathalyzer test for alcohol.
  13. Subjects with medically significant abnormal laboratory test results, vital sign results, or findings.
  14. Subjects who received transcranial magnetic stimulation or electroconvulsive therapy within 60 days of screening.
  15. Any condition possibly affecting drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).
  16. Subjects with difficulty swallowing.
  17. Subjects with a history of neuroleptic malignant syndrome.
  18. Subject who refuses to abstain from grapefruit-containing foods or beverages, or Seville orange-containing foods or beverages.

Cohorts 1 Through 5 (Part A) Subjects are excluded from the trial (Cohorts 1 through 5) if any of the following additional criteria apply:

  1. Subjects who have experienced psychosis requiring hospitalization within the 6 months prior to signing ICF.
  2. Subjects who experienced psychosis requiring a change in their antipsychotic medication (either drug type or dose) within the 3 months prior to signing ICF.
  3. Subjects who fulfill any of the following dietary restrictions: • History of chronic consumption of >400 mg/day of caffeine-containing drinks or food • Refuses to abstain from caffeine-containing foods or caffeinated beverages for 48 hours prior to Day -1 through Follow up Visit • Refuses to abstain from alcohol from 7 days prior to Day -1 through Follow-up Visit
  4. Subjects who have participated in any clinical trial within 60 days prior to signing ICF.
  5. Subjects with a 12-lead ECG demonstrating any of the following:

    • Abnormal ST-T-wave morphologies that may interfere with analysis, such as flat or poorly defined end of the T wave or prominent U waves
    • Left ventricular hypertrophy
    • QT interval corrected for heart rate QTcF >450 msec
    • QRS interval >110 msec
    • Left or right bundle branch block
    • PR interval >240 msec
    • Heart rate \<50 bpm or >90 bpm
    • Second- or third-degree atrioventricular block
  6. Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg at Screening or Day -1, will be taken with subjects in the supine/semi-recumbent position, or symptomatic hypotension, or orthostatic hypotension, which is defined as a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic blood pressure after at least 3 minutes of standing compared with the immediately previous supine blood pressure. Subjects who are receiving chronic treatment with antihypertensive medications at Screening are also excluded.

Cohort 6 (Part B) Only Subjects are excluded from trial (Cohort 6 only) if any of the following additional criteria apply:

  1. Subjects who have been hospitalized >14 days for the current episode of schizophrenia at the time of signing the ICF, excluding hospitalization for psychosocial reasons.
  2. Subjects presenting with a first episode of schizophrenia, based on clinical judgment of the investigator.
  3. Subjects with a 12-lead ECG exclusion as in Part A but will allow right bundle branch block in Part B.
  4. Systolic blood pressure >130 mmHg and/or diastolic blood pressure >80 mmHg at Screening or Day -1 and subjects with orthostatic hypotension, defined as a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic blood pressure after at least 3 minutes of standing compared with the average resting supine/semi-recumbent blood pressure at Screening or Day -1, will be excluded. Subjects with a heart rate \<50 bpm or >90 bpm. Subjects who are receiving chronic treatment with antihypertensive medications at Screening are also excluded.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    Part A: 5 mg QD CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part A: 5 mg QD Placebo

    Matching Placebo; Oral Dose

    Drug: Matching Placebo

  • Active comparator
    Part A: 10 mg QD CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part A: 10 mg QD Placebo

    Matching Placebo; Oral Dose

    Drug: Matching Placebo

  • Active comparator
    Part A: 20 mg QD CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part A: 20 mg QD Placebo

    Matching Placebo; Oral Dose

    Drug: Matching Placebo

  • Active comparator
    Part A: 5-10-20 mg BID CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part A: 5-10-20 mg BID Placebo

    Matching Placebo; Oral Dose

    Drug: Matching Placebo

  • Active comparator
    Part A: 30 mg QD CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part A: 30 mg QD Placebo

    Matching Placebo; Oral Dose

    Drug: Matching Placebo

  • Active comparator
    Part B 30 mg QD CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part B 30 mg QD Placebo

    Matching Placebo; Oral Dose

    Drug: Matching Placebo

  • Active comparator
    Part B 20 mg BID CVL-231

    Oral Dose

    Drug: CVL-231

  • Placebo comparator
    Part B 20 mg BID Placebo

    Drug: Matching Placebo

Interventions

  • CVL-231

  • DrugMatching Placebo

    Placebo matching CVL-231

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Includes Incidence of Significant ECG Abnormalities Occurring Post-Baseline, significant changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature), and changes in laboratory measures (hematology, serum chemistry and urinalysis)

    Time frame: Up to Day 72

  2. Incidence of suicidality as assessed by Columbia-Suicide Severity Rating Scale(C-SSRS)

    The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

    Time frame: Up to Day 72

  3. Change from Baseline of Simpson-Angus Scale (SAS) Results

    Evaluating Extrapyramidal symptoms using the SAS. The SAS consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.

    Time frame: Up to Day 72

  4. Change from Baseline of Abnormal Involuntary Movement Scale (AIMS) Results

    The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the subject is at rest, and the investigator also makes global judgments on the subject's dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the subject's dental status. The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements).

    Time frame: Up to Day 72

  5. Change from Baseline of Barnes Akathisia Rating Scale (BARS) Results

    Evaluating Extrapyramidal symptoms using the BARS. The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the subject, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.

    Time frame: Up to Day 72

Secondary outcomes

  1. Single-dose: Area under the plasma concentration vs. time curve (AUC) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 1

  2. Single-dose: Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 1

  3. Single-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 1

  4. Single-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 1

  5. Single-dose: Metabolite to parent ratio for AUC tau for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 1

  6. Multiple-dose: Steady state CVL-231 Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  7. Multiple-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  8. Multiple-dose: Trough plasma concentration (Ctrough) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  9. Multiple-dose: Minimum blood plasma concentration (Cmin) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  10. Multiple-dose: Area under the plasma concentration-time curve (AUCτ) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  11. Multiple-dose: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  12. Multiple-dose: Apparent Total Clearance of Drug from plasma: CL/F for CVL-231

    Time frame: Days 14 and/or 28 and/or 36

  13. Multiple-dose: Steady-state average plasma drug concentration: Css for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  14. Multiple-dose: Peak Trough Ratio (PTR) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  15. Multiple-dose: Accumulation ratio calculated from Cmax,ss and Cmax after single dosing (Rac, Cmax) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  16. Multiple-dose: Accumulation ratio calculated from AUCτ,ss and AUCτ after single dosing (Rac, AUC) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28 and/or 36

  17. Multiple-dose: Elimination half-life (t½) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 14-17 and/or Day 28-31

  18. Multiple-dose: Elimination rate constant (kel) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Day 14-17 and/or Day 28-31

  19. Multiple-dose: Ae (amount eliminated unchanged in urine) for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28

  20. Multiple-dose: Renal clearance for parent only for CVL-231

    Time frame: Days 14 and/or 28

  21. Multiple-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28

  22. Multiple-dose: Metabolite to parent ratio for AUCtau for CVL-231 and Metabolite (PF-06892787)

    Time frame: Days 14 and/or 28

07

Study locations

5 sites
  • Pillar Clinical Research
    Bentonville, Arkansas 72712, United States
  • Woodlands International Research Group
    Little Rock, Arkansas 72211, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in May 2021, 18 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 18 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2019
First posted
Oct 23, 2019
StartActual
Oct 15, 2019
Primary completionActual
May 7, 2021
CompletionActual
Jun 3, 2021
Last update
Jul 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04136873
Responsible party
Sponsor
First posted
Oct 23, 2019
Start date
Oct 15, 2019
Primary completion
May 7, 2021
Completion
Jun 3, 2021
Last update
Jul 2, 2021

Study contacts

Matthew Leoni, MD
study director · Cerevel Therapeutics, LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion